Prior Authorization Is a Clinical Problem. The Paperwork Is Just Where It Shows Up.

Every working clinician has a version of this story. A patient comes in, a treatment decision gets made, and then a wall appears between that decision and the patient receiving it. The wall is called prior authorization, and the instinct is to hand it to someone at the front desk and move on. That instinct is costing patients.

Prior authorization requires a prescriber or ordering clinician to get advance approval from a health plan before a drug, procedure, imaging study, or referral is covered. The stated rationale is utilization management: making sure expensive or potentially unnecessary care gets a second look before the insurer pays for it. The mechanism was not designed to be cruel. But its effects on clinical care are well-documented and worth naming plainly.

The most direct clinical harm is delay. For a patient with a new cancer diagnosis waiting on approval for a first-line chemotherapy regimen, days matter. For a patient in a mental health crisis whose psychiatrist has determined that a specific medication represents the best option, a week-long approval process is not an administrative inconvenience. It is a treatment gap. Oncologists, psychiatrists, and cardiologists see this differently than a primary care physician managing a stable chronic condition, and the variation matters. Delay is not one thing.

Then there is abandonment. Research across drug classes consistently shows that a meaningful share of patients, when they encounter an authorization barrier, simply do not complete the process. They stop. They go without. In populations managing multiple conditions, or patients with lower health literacy, or patients who work jobs that do not allow them to spend forty minutes on hold with an insurance line, the drop-off rate rises. The burden falls unevenly, and it falls hardest on people who were already less likely to navigate health systems smoothly.

There is a subtler effect that gets less attention. Prior authorization shapes what physicians prescribe prospectively, before the form even appears. Clinicians learn which drugs trigger lengthy reviews and begin defaulting to second choices not because those choices are clinically superior for the patient in front of them but because they are less likely to get stuck. This is called induced practice change, and it runs quietly in the background of clinical decision-making in ways that are almost impossible to measure in aggregate. Individual clinicians may not consciously recognize they are doing it.

None of this argues that all prior authorization is unjustifiable. Some high-cost interventions do benefit from structured review. The question is calibration. When a plan requires prior authorization for a generic medication with a decades-long safety record, or for a referral to a specialist in a condition the primary care physician is not trained to manage, the utilization management rationale gets thin. The burden shifts from the insurer to the clinician to the patient, and the patient rarely wins that three-way exchange.

Professional medical societies have pushed for gold-carding provisions, which exempt clinicians with high approval rates from repeated authorization requirements for certain services. Several states have enacted gold-carding rules. Federal regulators have examined response-time requirements. These are structural reforms, and they address part of the problem.

But the framing still matters. When prior authorization is described as a billing and coding issue, it gets assigned to administrative staff, and the clinical dimension disappears. The patient waiting on a medication approval is not waiting on paperwork. They are waiting on care. That distinction belongs in every conversation about how to fix the system.